Camilla Jessen
Known for helping with weight loss and diabetes, Ozempic and Mounjaro are now being linked to lower risks of cancer.
Others are reading now
New research suggests that popular weight loss medications like Ozempic and Mounjaro may provide unexpected health benefits far beyond trimming your waistline.
You might think Ozempic is just for weight loss—but its surprising impact is now catching researchers’ attention.
These widely used drugs, known for their role in managing type 2 diabetes and obesity, have now been linked to additional, potentially life-saving effects.
According to a new large-scale study published in JAMA Network Open, the medications may significantly reduce the risk of developing several obesity-related cancers.
GLP-1 receptor agonists— the drug class to which Ozempic and Mounjaro belong—were originally developed to regulate blood sugar. Their appetite-suppressing effects have since made them popular for weight management.
But now, evidence is emerging that their benefits go much further.
A New Ally in Cancer Prevention?
The study, which analyzed data from over 1.6 million patients with type 2 diabetes, found that those using GLP-1 medications had a notably lower risk of developing 10 types of cancer—most commonly pancreatic, liver, colon, and ovarian cancers—compared to patients treated with insulin.
Some cancer risks were reduced by as much as 65%.
Although it remains unclear whether the cancer protection stems directly from the medications or from resulting weight loss, researchers suggest several possible explanations: improved hormone regulation, reduced inflammation, and better dietary habits.
Promising, But Not a Magic Bullet
Still, experts caution against viewing these medications as miracle cures. The study is observational, not a controlled clinical trial, and many participants were on multiple treatments.
It’s also uncertain how consistently the medications were taken or whether users actually experienced weight loss.
Lifestyle remains a cornerstone of health. Regular exercise, balanced nutrition, and adequate sleep continue to be essential in reducing cancer risk—with or without medication.
Yet, these findings reveal that Ozempic and Mounjaro may offer more than expected—especially for patients with type 2 diabetes who are also managing obesity.
This article is based on information reported by National Geographic.